ExploreWatchlistsPricing
  1. JP-listed companies
  2. Shionogi & Co.,Ltd.
  3. Financials
  4. Stockholders' equity

Shionogi & Co.,Ltd. (4507)

Market cap
¥2.86T
P/E ratio
14.6x
Develops, manufactures and sells prescription pharmaceuticals globally, specializing in infectious diseases and central nervous system disorders.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Period EndStockholders' equity (Million JPY)YoY (%)
Mar 31, 20251,362,497+8.78%
Mar 31, 20241,252,562+11.65%
Mar 31, 20231,121,878+12.95%
Mar 31, 2022993,285+14.89%
Mar 31, 2021864,550+13.07%
Mar 31, 2020764,611+13.71%
Mar 31, 2019672,429+11.17%
Mar 31, 2018604,840+14.94%
Mar 31, 2017526,211+2.40%
Mar 31, 2016513,877+7.31%
Mar 31, 2015478,883+2.36%
Mar 31, 2014467,836

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat